Collectively, these experiments provide evidence that ALK-overexpressing prostate cancers can be targeted with small-molecule ALK inhibitors and suggest that ALK inhibitors might represent a potential therapeutic option for advanced prostate cancers with high ALK expression. This evidence concerns the gene ALK and prostate carcinoma.